epidermal-growth-factor and veliparib

epidermal-growth-factor has been researched along with veliparib* in 1 studies

Other Studies

1 other study(ies) available for epidermal-growth-factor and veliparib

Article	Year
Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells. Biochemical and biophysical research communications, 2013, Dec-06, Volume: 442, Issue:1-2 Though poly(ADP-ribose) polymerase 1 (PARP1) inhibitors have benefits in combination with radiotherapy in prostate cancers, few is known about the exactly role and underlying mechanism of PARP1 in combination with chemotherapy agents. Here our data revealed that inhibition of PARP1 by small interfering RNA (siRNA) could enhance docetaxel's activity against PC3 cells, which is associated with an accelerate repression of EGF/Akt/FOXO1 signaling pathway. Our results provide a novel role of PARP1 in transcription regulation of EGFR/Akt/FOXO1 signaling pathway and indicate that PARP1 siRNA combined with docetaxel can be an innovative treatment strategy to potentially improve outcomes in CRPC patients. Topics: Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cellular Senescence; Docetaxel; Drug Resistance, Neoplasm; Epidermal Growth Factor; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Knockdown Techniques; Humans; Male; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Taxoids	2013

Article

Year

Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells.

Biochemical and biophysical research communications, 2013, Dec-06, Volume: 442, Issue:1-2

Though poly(ADP-ribose) polymerase 1 (PARP1) inhibitors have benefits in combination with radiotherapy in prostate cancers, few is known about the exactly role and underlying mechanism of PARP1 in combination with chemotherapy agents. Here our data revealed that inhibition of PARP1 by small interfering RNA (siRNA) could enhance docetaxel's activity against PC3 cells, which is associated with an accelerate repression of EGF/Akt/FOXO1 signaling pathway. Our results provide a novel role of PARP1 in transcription regulation of EGFR/Akt/FOXO1 signaling pathway and indicate that PARP1 siRNA combined with docetaxel can be an innovative treatment strategy to potentially improve outcomes in CRPC patients.

Topics: Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cellular Senescence; Docetaxel; Drug Resistance, Neoplasm; Epidermal Growth Factor; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Knockdown Techniques; Humans; Male; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Taxoids

2013